Search Results - michael+sierks

11 Results Sort By:
Antibody based reagents that specifically recognize toxic oligomeric forms of beta-amyloid
Neurodegenerative diseases such as Alzheimer’s are affecting an increasing number, with annual new diagnoses approaching one-half million; and total cost, $150 billion. Early diagnosis and treatment are important for optimal outcomes, yet there is currently no test to detect such diseases in their early, asymptomatic stages. Active immuniza-tion...
Published: 8/27/2025   |   Inventor(s): Michael Sierks, Srinath Kasturirangan
Keywords(s): Bio-Technology, Therapeutics
Category(s): Life Science (All LS Techs), Diagnostic Assays/Devices, Neurodegenerative Disease Technologies, Non-Cancer Therapeutics, Proteomic Assays/Reagents/Tools, Medical Diagnostics/Sensors
Targets and Methods of Diagnosing, Monitoring & Treating Frontotemporal Dementia
Diverse pathologies, especially related to early protein misfolding and aggregation, are observed in different neurodegenerative diseases. Some protein variants result in different proteinopathies that vary from patient to patient, highlighting a need for personalized diagnostic tests to enable accurate diagnoses. Frontotemporal dementia (FTD) refers...
Published: 8/27/2025   |   Inventor(s): Stephanie Williams, Michael Sierks
Keywords(s):  
Category(s): Bioanalytical Assays, Chemistries & Devices, Diagnostic Assays/Devices, Medical Diagnostics/Sensors, Life Science (All LS Techs), Proteomic Assays/Reagents/Tools, Neurodegenerative Disease Technologies
Reagents Targeting Neurodegenerative Diseases and Traumatic Brain Injury
Misfolding and aggregation of proteins, such as beta-amyloid (Aß), alpha-synuclein (a-syn), tau and TAR DNA-binding protein 43 (TDP-43), have been strongly correlated with early onset of neurodegenerative diseases such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Frontotemporal Dementia (FTD), amyotrophic lateral sclerosis (ALS) and...
Published: 8/27/2025   |   Inventor(s): Michael Sierks, Stephanie Williams
Keywords(s): Alzheimer's Disease, Bioassay, biomarker, Neurodegenerative Disorders, Neurological Disorders
Category(s): Bioanalytical Assays, Chemistries & Devices, Diagnostic Assays/Devices, Life Science (All LS Techs), Neurodegenerative Disease Technologies, Proteomic Assays/Reagents/Tools, Non-Cancer Therapeutics
Reagents Targeting Neurodegenerative Diseases and Traumatic Brain Injury
Misfolding and aggregation of proteins, such as beta-amyloid (Aß), alpha-synuclein (a-syn), tau and TAR DNA-binding protein 43 (TDP-43), have been strongly correlated with early onset of neurodegenerative diseases such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Frontotemporal Dementia (FTD), amyotrophic lateral sclerosis (ALS) and...
Published: 8/27/2025   |   Inventor(s): Michael Sierks, Lalitha Venkataraman, Wei Xin
Keywords(s): Alzheimer's Disease, CNS Therapeutics, Dementias, Neurodegenerative Disorders, Neurological Disorders, Phage display
Category(s): Bioanalytical Assays, Chemistries & Devices, Diagnostic Assays/Devices, Life Science (All LS Techs), Neurodegenerative Disease Technologies, Non-Cancer Therapeutics, Proteomic Assays/Reagents/Tools
Reagents Targeting Neurodegenerative Diseases and Traumatic Brain Injury
Misfolding and aggregation of proteins, such as beta-amyloid (Aß), alpha-synuclein (a-syn), tau and TAR DNA-binding protein 43 (TDP-43), have been strongly correlated with early onset of neurodegenerative diseases such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Frontotemporal Dementia (FTD), amyotrophic lateral sclerosis (ALS) and...
Published: 8/27/2025   |   Inventor(s): Michael Sierks, Stephanie Williams, Lalitha Venkataraman
Keywords(s): AFM, Antibody Therapeutics, Antigen-specific Therapies, Bioassay, Bio-Technology, CNS Therapeutics, Therapeutics
Category(s): Life Science (All LS Techs), Neurodegenerative Disease Technologies, Non-Cancer Therapeutics, Proteomic Assays/Reagents/Tools, Bioanalytical Assays, Chemistries & Devices, Diagnostic Assays/Devices
Reagents Targeting Neurodegenerative Diseases and Traumatic Brain Injury
Misfolding and aggregation of proteins, such as beta-amyloid (Aß), alpha-synuclein (a-syn), tau and TAR DNA-binding protein 43 (TDP-43), have been strongly correlated with early onset of neurodegenerative diseases such as Alzheimer's Disease (AD), Parkinson's Disease (PD), Frontotemporal Dementia (FTD), amyotrophic lateral sclerosis (ALS) and...
Published: 2/13/2025   |   Inventor(s): Michael Sierks, Stephanie Williams
Keywords(s): Antibodies, Antigen-specific Therapies, Bioassay, biomarker, ELISA, Mental Disorders, Traumatic Brain Injury
Category(s): Bioanalytical Assays, Chemistries & Devices, Diagnostic Assays/Devices, Life Science (All LS Techs), Neurodegenerative Disease Technologies, Non-Cancer Therapeutics, Proteomic Assays/Reagents/Tools
Recombinant Antibody Fragments that Selectively Target Oligomeric Tau Aggregates
Alzheimer's disease (AD) is one of the most prevalent and feared neurodegenerative diseases associated with aging, characterized by progressive neuronal loss and cognitive dysfunction. AD affects nearly 5 million Americans, and unfortunately, there is no cure as of yet. Numerous studies have implicated oligomeric amyloid beta (Aß) aggregates as...
Published: 2/13/2025   |   Inventor(s): Michael Sierks, Huilai Tian, James Moe, Eliot Davidowitz
Keywords(s): Antibodies, Antibody Therapeutics, Antigen-specific Therapies, Bioassay, Dementias, Diagnostics, Human aging, Protein, Therapeutics
Category(s): Life Science (All LS Techs), Neurodegenerative Disease Technologies, Non-Cancer Therapeutics, Diagnostic Assays/Devices, Medical Diagnostics/Sensors, Proteomic Assays/Reagents/Tools
Nanoscale Process to Generate Reagents Selective for Individual Protein Variants
Protein variants have been associated with many different and devastating human diseases including Alzheimer’s and Parkinson’s diseases, diabetes and cancer. Unfortunately, assessment of these protein variants is technologically difficult, primarily owing to two factors: a lack of binding partners that can distinguish between protein isoforms...
Published: 2/13/2025   |   Inventor(s): Michael Sierks, Mark Hayes
Keywords(s):  
Category(s): Bioanalytical Assays, Chemistries & Devices, Life Science (All LS Techs), Proteomic Assays/Reagents/Tools
Selective Clearance of Beta-Amyloid Using Bispecific Recombinant Antibody fragments
Alzheimer’s disease (AD) is one of the most prominent and feared neurodegenerative diseases associated with aging. A hallmark of this disease is the formation of extra-cellular amyloid plaques in the brain. The principle component of these extracellular plaques is amyloid-ß protein (Aß). Though the mechanisms underlying Alzheimer’s...
Published: 2/13/2025   |   Inventor(s): Michael Sierks, Yong Shen
Keywords(s):  
Category(s): Pharmaceuticals, Life Science (All LS Techs), Neurodegenerative Disease Technologies, Non-Cancer Therapeutics
Bi-specific Antibodies as a Therapeutic for Alzheimer’s Disease
Alzheimer’s disease (AD) is one of the most prominent and feared neurodegenerative diseases associated with aging. A hallmark of this disease is the formation of extra-cellular amyloid plaques in the brain. The principle component of these extracellular plaques is amyloid-ß protein (Aß). Though the mechanisms underlying Alzheimer’s...
Published: 2/13/2025   |   Inventor(s): Michael Sierks, Shanta Boddapati, Srinath Kasturirangan
Keywords(s): Bio-Technology, Therapeutics
Category(s): Life Science (All LS Techs), Neurodegenerative Disease Technologies, Non-Cancer Therapeutics, Pharmaceuticals
1 2